Richard Pzena
Pzena Investment Management
Richard Pzena Halozyme Therapeutics Inc stake
total: 584
Pzena Investment Management HALO trades
- Total transactions:
- 8
- New positions:
- 3
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2025 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Richard Pzena holds 4,049 Halozyme Therapeutics Inc (HALO) shares with a market value of roughly $316.92K accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $73.1 for "buy" trades and estimated average "sell" price is $64.63. Pzena Investment Management first purchased HALO in 2022 Q1, initially acquiring 15,738 shares. Richard Pzena later completely sold out the position and invested in Halozyme Therapeutics Inc again in 2025 Q3. Since the initial investment in Halozyme Therapeutics Inc (HALO), Pzena Investment Management has made 7 more transactions.
When did Richard Pzena buy Halozyme Therapeutics Inc (HALO)?
Richard Pzena first invested in Halozyme Therapeutics Inc (HALO) in 2022 Q1 at the reported quarter-end price of $39.90 per share.
What's the cost basis of Pzena Investment Management's HALO stake?
The estimated cost basis for Halozyme Therapeutics Inc (HALO) stake is around $73.10 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $73.10
- Weighted AVG sell price:
- $64.63
Richard Pzena's historical trades in Halozyme Therapeutics Inc
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
4,049
|
$64.63
|
$261,687
|
-5.35% (-229)
|
-0%
|
|
2025 Q4
|
0.00%
|
4,278
|
$67.30
|
$287,909
|
+4.16% (+171)
|
+0%
|
|
2025 Q3
|
0.00%
|
4,107
|
$73.34
|
$301,207
|
new
|
+0%
|
|
2023 Q2
|
0.00%
|
0
|
$38.19
|
|
-100% (-9,216)
|
-0%
|
|
2023 Q1
|
0.00%
|
9,216
|
$38.19
|
$351,959
|
-36.47% (-5,291)
|
-0%
|
|
2022 Q4
|
0.00%
|
14,507
|
$56.90
|
$825,448
|
new
|
+0%
|
|
2022 Q2
|
0.00%
|
0
|
$39.90
|
|
-100% (-15,738)
|
-0%
|
|
2022 Q1
|
0.00%
|
15,738
|
$39.90
|
$628,000
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.